A Study of Drug-Drug Interaction Between Danoprevir/Low-Dose Ritonavir and Raltegravir in Healthy Volunteers

Inclusion Criteria:

- Healthy non-smoking male and female adults, 18 - 55 years of age, inclusive

- Healthy status defined by absence of evidence of any active or chronic disease

- Medical history without major, recent, or ongoing pathology

- Weight >/= 50.0 kg

- Body mass index (BMI) 18.0 - 32-0 kg/m2

- Willingness to abstain from alcohol, xanthine-containing beverages or food (e.g.
coffee, tea, cola, chocolate, "energy drinks") from 48 hours prior to entry in the
clinical site until discharge

- Females of child-bearing potential and males and their female partners of
child-bearing potential must agree to use 2 forms of contraception, one of which must
be a barrier method, during the study and for 90 days after the last drug
administration. Acceptable barrier forms of contraception are condom and diaphragm;
acceptable non-barrier forms of contraception for this study are non-hormonal
intrauterine device (IUD) and/or spermicide

Exclusion Criteria:

- Pregnant or lactating females or males with female partners who are pregnant or
lactating

- Any history of clinically significant cardiovascular or cerebrovascular disease,
hypertension, and/or infections

- Positive test for drugs of abuse at screening or prior to admission to the clinical
site during any study period

- Positive for hepatitis B, hepatitis C or HIV infection

- Current smokers or subjects who have discontinued smoking less than 6 months prior to
first dose of study medication

- Use of hormonal contraceptives within 30 days before the first dose of study
medication

- History of clinically significant drug-related allergy (such as anaphylaxis) or
hepatotoxicity